NCT06569459View on ClinicalTrials.gov

Trilaciclib Combined With Concurrent Chemoradiotherapy and Immunotherapy in the Treatment of Esophageal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 9, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

July 31, 2026

Conditions
Esophageal Cancer
Interventions
DRUG

Trilaciclib Injection [Cosela]

Chemoradiotherapy and immunotherapy with Trilaciclib in the treatment of patients with unresectable locally advanced esophageal squamous cell carcinoma

DRUG

Placebo

Chemoradiotherapy and immunotherapy in the treatment of patients with unresectable locally advanced esophageal squamous cell carcinoma

Trial Locations (1)

210029

RECRUITING

The First Affiliated Hospital of Nanjing Medical University, Nanjing

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER